Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.48 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448853 | 0.93 | BACE1 (0.55) | BACE1ENPEPTASP1BACE2 | |
| SCHEMBL30163257 | 0.92 | ENPEP (0.51) | BACE1ENPEPBACE2FOLH1MDM4 | |
| SCHEMBL29378835 | 0.90 | ENPEP (0.54) | BACE1ENPEPTASP1BACE2FOLH1 | |
| SCHEMBL29931588 | 0.89 | ENPEP (0.53) | BACE1ENPEP | |
| SCHEMBL29931628 | 0.89 | ENPEP (0.53) | BACE1ENPEP | |
| SCHEMBL30512767 | 0.89 | BACE1 (0.53) | BACE1ENPEPTASP1 | |
| SCHEMBL30163386 | 0.88 | BACE1 (0.46) | BACE1ENPEPTASP1BACE2MDM4 | |
| SCHEMBL29405906 | 0.86 | TASP1 (0.55) | BACE1ENPEPTASP1BACE2FOLH1 | |
| SCHEMBL24725397 | 0.86 | BACE1 (0.52) | BACE1ENPEPBACE2MDM4MDM2 | |
| SCHEMBL31491410 | 0.85 | ENPEP (0.57) | BACE1ENPEPTASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | PEPTISTAR INC. (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4365184-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | Peptistar Inc. (JP) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023277186-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | ペプチスター株式会社 | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | HDGF, VIP, NPPA | BACE1 3899/4885ENPEP 23/4885TASP1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.